ASAkihiro Sakurai

Akihiro Sakurai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akihiro Sakurai has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 May 2012
      • p. 801-5

    [Genetic medicine in diabetes: current status and the future].

    by Akihiro Sakurai, Yoshimitsu Fukushima

  • Familial neuroendocrine tumor syndromes: From genetics to clinical practice

    by Akihiro Sakurai, Miyuki Katai, Kiyoshi Hashizume, Yoshimitsu Fukushima

    Thanks to recent developments in molecular biology and cancer genetics, genetic testing has become widely available and useful in several kinds of familial tumor syndrome. However, the impact of genetic testing on medical management is not always straightforward. Clinicians have to consider the psychological impact and ethical complexities of communicating hereditary cancer risk information to families. This review notes some points on genetic counseling before and after genetic testing for familial neuroendocrine tumor syndromes.


  • Open Access

    Novel 14 Base-Pair Deletion of the MEN1 Gene in a Patient with Recurrent Primary Hyperparathyroidism

    by Miyuki Katai, Akihiro Sakurai, Shinya Uchino, Kesami Minemura, Kiyoshi Hashizume, Yoshimitsu Fukushima

    MEN1 is the causative gene for multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome characterized by hyperplastic and neoplastic disorder of endocrine organs such as parathyroid, anterior pituitary and gastroenteropancreatic endocrine tissues. More than 300 germline mutations have already been reported in patients with MEN1. We here report a novel deletional mutation identified in a Japanese woman with apparently sporadic recurrent hyperparathyroidism. Genetic testing revealed a heterozygous deletion involving 14 bp in exon 6 (starting at amino acid codon 293) of MEN1, which results in early termination of the protein. This deletional mutation has not previously been described elsewhere.

  • Clinical and Genetic Features of Patients with Multiple Endocrine Tumors Who Have neither Family History nor MEN1 Germline Mutations

    by Akihiro Sakurai, Miyuki Katai, Wataru Yumita, Kesami Minemura, Kiyoshi Hashizume

    Multiple endocrine neoplasia type 1 (MEN1) is an hereditary tumor syndrome that involves specific endocrine organs such as parathyroids, anterior pituitary gland, and endocrine pancreas. The responsible gene for this syndrome, MEN1, has been isolated and that enabled genetic diagnosis for patients with endocrine tumors and early detection of asymptomatic gene carriers in affected families. Nevertheless, there are a considerable number of patients with MEN1 who have neither family history nor germline MEN1 mutations. In this article, clinical features of such patients are described. Among 53 MEN1 patients we have seen during the last 20 yr, five patients who did not have either MEN1 germline mutation or family history were categorized as MEN1 phenocopy. During the same period, we have also experienced three patients who had primary hyperparathyroidism and adrenocortical tumor but had no apparent family history of endocrine tumors. These patients were considered as MEN1 phenocopy variants and included in the study. The mean age of MEN1 phenocopy patients (including variants) at diagnosis was 48 yr, which was not significantly different from that of probands of familial MEN1 (46 yr) who carry heterozygous MEN1 gene mutations. In the majority of MEN1 phenocopy patients, primary hyperparathyroidism was due to a single parathyroid adenoma. In contrast to a previous report, we found that MEN1 phenocopy patients are not necessarily older than probands of familial MEN1. Phenotypic expression of such patients is variable, thus differentiation of familial MEN1 and MEN1 phenocopy cannot be made based on age and clinical phenotype alone.


    • 1 August 2002
      • p. 293-7

    [Genetic test and genetic counseling of diabetes].

    by Akihiro Sakurai, Yoshimitsu Fukushima

    • 1 April 2002
      • Vol. 29  (4) , 502-7

    [Genetic testing and counseling for familial tumor syndromes].

    by Miyuki Katai, Akihiro Sakurai, Yoshimitsu Fukushima

    Recent developments in molecular biology have increased our understanding of the genetics of familial tumor syndromes. Isolation of the responsible genes has made it possible to identify gene carriers before they manifest clinical symptoms, which enables early detection of disease and at times prophylactic surgery. Indications for genetic testing of susceptible family members, however, should be carefully considered. Genetic counseling must be provided to clients before genetic tests. Patients should be provided with the latest knowledge on the disease and appropriately informed of the benefits and possible problems associated with genetic test, as such information is essential for clients to decide whether they will undergo such tests. Genetic medicine is not sufficiently available at present in Japan. Establishment of genetic services that deal with genetic counseling, family support and ethical, social and legal issues is strongly desired.

  • Insulinoma in a Patient with Non-Insulin-Dependent Diabetes Mellitus.

    by Akihiro Sakurai, Toru Aizawa, Masafumi Katakura, Yoshihiko Sato, Gengo Kaneko, Kunio Yoshizawa, Kiyoshi Hashizume

    Insulinoma in a patient with pre-existing diabetes is exceedingly rare. Only a small number of well-documented cases have been reported in the world during the last 40 years. We describe a case with non-insulin-dependent diabetes mellitus who after seven years of sulfonylurea treatment experienced recurrent episodes of hypoglycemia. Endogenous hyperinsulinism was found and radiographical examination and transhepatic venous sampling confirmed an insulin secreting pancreatic tumor. After surgical excision of the tumor, patient was relieved from hypoglycemic attacks but required to initiate insulin injection for the treatment of hyperglycemia.


  • Induction of Cytosolic Triiodo-L-Thyronine (T3) Binding Protein (CTBP) by T3 in Primary Cultured Rat Hepatocytes.

    by Yutaka Nishii, Kiyoshi Hashizume, Kazuo Ichikawa, Teiji Takeda, Mutsuhiro Kobayashi, Takeshi Nagasawa, Miyuki Katai, Hiroaki Kobayashi, Akihiro Sakurai

    Cytosolic 3, 5, 3'-triiodo-L-thyronine (T3)-binding protein (CTBP) plays an important role in the regulation of intracellular T3 translocation from cytoplasm to the nuclear T3 receptor. We examined whether the CTBP activity could be induced by T3 or not in cultured hepatocytes prepared from thyroidectomized rats. CTBP activity was not detected in primary cultured hepatocytes from thyroidectomized rats. However, the protein was induced by the addition of T3 to the culture medium. The increase in the activity of CTBP was time dependent and the maximal level was obtained by 48 h in the presence of 300 nM T3. CTBP activity was also increased by retinol (35 microM) or by 1,25-(OH)2-vitamin D3 (10 nM). On the other hand, the activity of malic enzyme (ME) was induced by the addition of T3 to the culture medium. The maximal activity of ME was obtained by 48 h in the presence of 300 nM T3. The increase in ME activity was also induced by retinol or 1,25-(OH)2-vitamin D3. These results suggested that not only ME activity but also CTBP activity is induced by T3. Further, retinol and vitamin D3 have similar effects on the induction of CTBP activity and ME activity.